C difficile Vaccine Study | Central Kentucky Research
AMR performs phase I, II, III, and IV clinical research trials to support pharmaceutical companies in the development of new drugs, devices, and vaccines at 17 locations across the United States. Over 24 years ago, AMR owners began collaborating based on their mutual respect and shared values. Relationships are the foundation of AMR’s success. Our flexible solutions propel clinical trials from ideas to reality through relationships with industry experts you know. To learn more about AMR’s fully integrated network, click here: amrllc.com.


C difficile Vaccine Study

  • May 18, 2017

The purpose of this study is to find out if an investigational vaccine prevents severe diarrhea caused by a germ (bacterium) called Clostridium difficile (C diff).  Vaccines help your body to make antibodies which help to fight against diseases (also called an immune response).  C diff is a significant cause of infectious diarrhea.  Its severity can range from being mild to severe, and can lead to death.

To qualify for this study, you must be at least 60 years of age AND:

  • Have had at least one (1) inpatient hospitalization for at least 2 nights within the past 12 months, OR …
  • Have had at least 2 emergency room visits within the past 12 months, OR …
  • Have had at least 10 outpatient visits to your doctor within the past 12 months, OR …
  • Reside in a nursing home or skilled nursing facility, OR …
  • Have received systemic (oral or injected) antibiotics at any time within the past 12 weeks
  • (Other criteria also apply.)

This study will last up to 3 1/2 years and would require at least 5 visits to CKRA over that period of time.  Qualified participants will receive all study-related medical exams, lab tests, and investigational vaccine or inactive placebo at no cost, and compensation is available for your time and travel.

For more information or to see if you may qualify, call 859-264-8999.